Source F1000 Prime: Fox et al. present the results of the eagerly awaited SPRINT-MS trial – a multi-centre phase II double 
blinded placebo controlled study of ibudilast in decreasing brain atrophy in progressive forms of multiple sclerosis (MS).
Ibudilast was previously trialled in relapsing MS and whilst it did not prevent the reduction of new T2 lesions, it had an effect on decreasing brain atrophy and conversion of gadolinium-enhancing lesions to T1 black holes. Coupled with its immunomodulation properties and ability to cross the blood-brain barrier, ibudilast was felt to be worth studying in progressive MS (PMS). Read on (click on the abstract tab)